Results 271 to 280 of about 589,499 (392)

Relevance of G protein‐coupled receptor (GPCR) dynamics for receptor activation, signalling bias and allosteric modulation

British Journal of Pharmacology, EarlyView.
Abstract G protein‐coupled receptors (GPCRs) are one of the major drug targets. In recent years, computational drug design for GPCRs has mainly focused on static structures obtained through X‐ray crystallography, cryogenic electron microscopy (cryo‐EM) or in silico modelling as a starting point for virtual screening campaigns. However, GPCRs are highly
Marta Lopez‐Balastegui, Tomasz Maciej Stepniewski, Małgorzata M. Kogut‐Günthel, Antonella Di Pizio, Mette Marie Rosenkilde, Jiafei Mao, Jana Selent   +6 more
wiley   +1 more source

Prolactin-secreting tumors, dopamine agonists and pregnancy: a longitudinal experience of a tertiary neuroendocrine center. [PDF]

Pituitary
Prencipe N, Bona C, Cuboni D, Berton AM, Bioletto F, Varaldo E, Aversa LS, Sibilla M, Gasco V, Ghigo E, Grottoli S.   +10 more
europepmc   +1 more source

Distinct Residues in the Carboxyl Tail Mediate Agonist-induced Desensitization and Internalization of the Human Dopamine D1 Receptor [PDF]

, 2002
Michael Lamey, Miles D. Thompson, George Varghese, Hong Chi, Marek Sawzdargo, Susan R. George, Brian F. O’Dowd   +6 more
openalex   +1 more source

Progress on the development of Class A GPCR‐biased ligands

British Journal of Pharmacology, EarlyView.
Class A G protein‐coupled receptors (GPCRs) continue to garner interest for their essential roles in cell signalling and their importance as drug targets. Although numerous drugs in the clinic target these receptors, over 60% GPCRs remain unexploited. Moreover, the adverse effects triggered by the available unbiased GPCR modulators, limit their use and
Paula Morales, Magdalena M. Scharf, Marcel Bermudez, Attila Egyed, Rafael Franco, Olivia K. Hansen, Nadine Jagerovic, Jan Jakubík, György M. Keserű, Dóra Judit Kiss, Pawel Kozielewicz, Olav Larsen, Maria Majellaro, Ana Mallo‐Abreu, Gemma Navarro, Rubén Prieto‐Díaz, Mette M. Rosenkilde, Eddy Sotelo, Holger Stark, Tobias Werner, Laura M. Wingler   +20 more
wiley   +1 more source

The early treatment of Parkinson's disease: levodopa, dopamine agonists or both

, 2000
M. B. Stern
openalex   +1 more source

Differential Effects of Direct and Indirect Dopamine Agonists on Prepulse Inhibition: A Study in D1 and D2 Receptor Knock-Out Mice [PDF]

, 2002
Rebecca J. Ralph-Williams, Virginia Lehmann-Masten, Veronica Otero-Corchón, Malcolm J. Low, Mark A. Geyer   +4 more
openalex   +1 more source

The Effect of Dopamine Agonists on Adaptive and Aberrant Salience in Parkinson's Disease

Neuropsychopharmacology, 2012
H. Nagy, E. Levy-Gigi, Z. Somlai, A. Takáts, D. Bereczki, S. Kéri   +5 more
semanticscholar   +1 more source

Preclinical models for evaluating psychedelics in the treatment of major depressive disorder

British Journal of Pharmacology, EarlyView.
Psychedelic drugs have seen a resurgence in interest as a next generation of psychiatric medicines with potential as rapid‐acting antidepressants (RAADs). Despite promising early clinical trials, the mechanisms which underlie the effects of psychedelics are poorly understood.
Laith Alexander, Dasha Anderson, Luke Baxter, Matthew Claydon, James Rucker, Emma S. J. Robinson   +5 more
wiley   +1 more source

The Australia story: Current status and future challenges for the clinical applications of psychedelics

British Journal of Pharmacology, EarlyView.
Abstract The past decade has seen a huge increase in clinical research with psychedelic drugs and 3,4‐methylenedioxymethamphetamine (MDMA), which have revealed great potential for treating mental health conditions. Given this progress in research, as well as the current unmet clinical need of millions of patients, in 2023, the Australian Therapeutic ...
David J Nutt, Peter Hunt, Anne Katrin Schlag, Paul Fitzgerald   +3 more
wiley   +1 more source

A rationale for dopamine agonists as primary therapy for Parkinson's disease.

, 1992
C. Warren Olanow
openalex